Angiotensin Receptor Neprilysin Inhibitor for the Treatment of Cardiovascular Diseases: A New Approach

ISSN： 2454-5996

Source： Hypertension Journal, Vol.2, Iss.3, 2016-07, pp. : 145-152

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A review of the angiotensin-converting enzyme inhibitor, zofenopril, in the treatment of cardiovascular diseases

By Borghi Claudio Bacchelli Stefano Degli Esposti Daniela Ambrosioni Ettore

Expert Opinion on Pharmacotherapy, Vol. 5, Iss. 9, 2004-09 ,pp. : 1965-1977

Informa Healthcare

Access to resources Recommend Favorite

Angiotensin-Receptor Neprilysin Inhibitor LCZ696；A Novel Therapy for Heart Failure

World Heart Journal, Vol. , Iss. , 2015-01 ,pp. : 23-26

Nova Science Publishers, Inc.

Access to resources Recommend Favorite

Angiotensin Receptor Blockers in Hypertension and Cardiovascular Diseases

Cardiovascular & Hematological Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Cardiovascular & Hematological Agents), Vol. 4, Iss. 1, 2006-01 ,pp. : 67-73

Bentham Science Publishers

Access to resources Recommend Favorite

Pharmacokinetic drug–drug interaction assessment between LCZ696, an angiotensin receptor neprilysin inhibitor, and hydrochlorothiazide, amlodipine, or carvedilol

Clinical Pharmacology In Drug Development, Vol. 4, Iss. 6, 2015-11 ,pp. : 407-417

John Wiley & Sons Inc

Access to resources Recommend Favorite

Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction

EUROPEAN JOURNAL OF HEART FAILURE, Vol. 17, Iss. 5, 2015-05 ,pp. : 510-517

John Wiley & Sons Inc

Access to resources Recommend Favorite